| scholarly article | Q13442814 |
| P50 | author | Nicoline Hoogerbrugge | Q56436866 |
| P2093 | author name string | Massuger LF | |
| Bulten J | |||
| Ligtenberg MJ | |||
| de Hullu JA | |||
| Oei AL | |||
| P2860 | cites work | Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing | Q79214311 |
| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 | ||
| Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 | Q28212276 | ||
| Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy | Q33968475 | ||
| Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation | Q34129784 | ||
| Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations | Q34129787 | ||
| Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up | Q34313361 | ||
| Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations | Q34506495 | ||
| Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence | Q35644167 | ||
| Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature | Q35894534 | ||
| Hereditary cancer predisposition syndromes | Q36002146 | ||
| Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. | Q50638328 | ||
| Prospectively detected cancer in familial breast/ovarian cancer screening. | Q50654339 | ||
| The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. | Q50660552 | ||
| Early detection of breast and ovarian cancer in families with BRCA mutations. | Q50757471 | ||
| Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. | Q50760539 | ||
| Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. | Q50767903 | ||
| Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. | Q50958716 | ||
| Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. | Q52123195 | ||
| Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer | Q56438023 | ||
| Ultrasound screening for familial ovarian cancer | Q67764093 | ||
| Location of BRCA1 in human breast and ovarian cancer cells | Q70998780 | ||
| Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study | Q73294203 | ||
| Use of CA-125 and ultrasound in high-risk women | Q77676299 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 814-819 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Surveillance of women at high risk for hereditary ovarian cancer is inefficient | |
| P478 | volume | 94 |
| Q38175815 | Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers |
| Q24651567 | Beyond CA125: the coming of age of ovarian cancer biomarkers |
| Q84960633 | CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: A population-based study |
| Q46109910 | Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers |
| Q37611320 | Determination of serum CRP, VEGF, Leptin, CK-MB, CA-15-3 and IL-6 levels for malignancy prediction in adnexal masses |
| Q30858808 | Development and preliminary evaluation of a multivariate index assay for ovarian cancer |
| Q35749439 | Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study |
| Q44498721 | Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers |
| Q39453522 | Epigenetic biomarkers in the diagnosis of ovarian cancer. |
| Q43199656 | Familial ovarian screening--effective or ineffective? |
| Q90131207 | Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations |
| Q37357662 | Genetics: breast cancer as an exemplar |
| Q83525183 | Hereditary breast and ovarian cancer syndrome |
| Q46449018 | Hereditary gynecologic cancers |
| Q38153188 | Hereditary ovarian and breast cancer: what have we learned? |
| Q34977063 | Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management |
| Q43199646 | High percentage of abnormal findings on TVU needs further discussion |
| Q37407195 | Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome |
| Q38073703 | Management of genetic syndromes predisposing to gynecologic cancers |
| Q35108393 | Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. |
| Q36610368 | No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study |
| Q37109290 | Predictors of choosing life-long screening or prophylactic surgery in women at high and moderate risk for breast and ovarian cancer |
| Q94340469 | Reply: Familial ovarian screening: how to address abnormal TVU findings and its influence on the efficacy of screening? |
| Q34622294 | SGO White Paper on ovarian cancer: etiology, screening and surveillance |
| Q35596203 | Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests. |
| Q37122297 | Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers |
| Q22252596 | The clinical management of BRCA1 and BRCA2 mutation carriers |
| Q36240959 | The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy |
| Q57307179 | Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands |
Search more.